Prime Medicine
PRME
125 hedge funds and large institutions have $120M invested in Prime Medicine in 2025 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 41 increasing their positions, 36 reducing their positions, and 29 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 36
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.01% less ownership
Funds ownership: 49.05% → 46.04% (-3%)
5% less funds holding
Funds holding: 132 → 125 (-7)
24% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 29
36% less capital invested
Capital invested by funds: $188M → $120M (-$67.6M)
49% less call options, than puts
Call options by funds: $120K | Put options by funds: $237K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.14M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$581K |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$422K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$352K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$269K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$5.24M |
| 2 |
WHG
Westwood Holdings Group
Dallas,
Texas
|
-$2.58M |
| 3 |
Walleye Capital
New York
|
-$1.18M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$850K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$810K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$18 | -6 | Closed |
|
|
C
152
Covestor
London,
United Kingdom
| – | +$48 | +19 | +136% |
|
|
AW
153
Avion Wealth
The Woodlands,
Texas
| – | +$454 | +178 | New |
|
PRME Hedge Fund Activity: Q1 2025 in Review
125 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Prime Medicine (PRME) for Q1 2025, worth a combined $120M — down 36% from $188M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of PRME and 22 opened new positions — a net loss of 7 holders — while 36 trimmed existing stakes and 41 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $1.14M. The largest seller was ARK Investment Management, cutting an estimated $5.24M.
- 125 institutional investors held Prime Medicine (PRME) as of Q1 2025, down from 132 in Q4 2024.
- Funds reported $120M of Prime Medicine stock for Q1 2025, down 36% quarter-over-quarter.
- 22 funds opened new Prime Medicine positions in Q1 2025 and 29 closed out, a net change of -7 holders.
- The largest Prime Medicine buyer in Q1 2025 was Renaissance Technologies, an estimated $1.14M added.
- The largest Prime Medicine seller in Q1 2025 was ARK Investment Management, an estimated $5.24M sold.
Based on aggregated 13F filings for Q1 2025.